Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

VeriSign (VRSN) To Report Q2 Earnings: What's In Store?

Published 07/21/2019, 11:10 PM
Updated 07/09/2023, 06:31 AM

VeriSign (NASDAQ:VRSN) is set to report second-quarter 2019 results on Jul 25.

Notably, the company’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average positive surprise being 10.8%.

VeriSign reported first-quarter 2019 non-GAAP earnings of $1.31 per share that beat the Zacks Consensus Estimate of $1.24. The figure increased 22.4% from the year-ago quarter.

Moreover, revenues increased 2.4% year over year to $306.4 million and beat the consensus mark of $302.4 million.

The Zacks Consensus Estimate for second-quarter earnings has been steady at $1.29 over the past 30 days. The consensus mark for revenues is pegged at $306.5 million, indicating an increase of 1.4% from the year-ago quarter’s reported figure.

The consistent increase in the number of .com and .net domain name registrations is likely to drive VeriSign’s top line in the to-be-reported quarter.

Management anticipates the renewal rate for first-quarter 2019 to be about 75% compared with 75.3% in the year-ago quarter. Renewal rates are not fully measurable until 45 days from the end of the quarter.

VeriSign, Inc. Price and EPS Surprise

VeriSign, Inc. price-eps-surprise | VeriSign, Inc. Quote

Moreover, on May 30, 2019, VeriSign announced that first-quarter 2019 closed with 351.8 million domain name registrations across all top-level domains (TLDs), up 0.9% year over year. Domain name registrations grew 18 million or 5.4% year over year.

However, increasing operating expenses related to research and development, and sales and marketing may prove to be a drag on margins in second-quarter 2019.

What Our Model Says

According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has a good chance of beating estimates. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided.

VeriSign has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks to Consider

Here are a few companies you may want to consider, as our model shows that these have the right combination of elements to post earnings beat in their upcoming releases:

Facebook (NASDAQ:FB) has an Earnings ESP of +0.61% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Apple (NASDAQ:AAPL) has an Earnings ESP of +1.35% and a Zacks Rank #3.

Grubhub (NYSE:GRUB) has a Zacks Rank #3 and an Earnings ESP of +23.79%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Facebook, Inc. (FB): Free Stock Analysis Report

VeriSign, Inc. (VRSN): Free Stock Analysis Report

Grubhub Inc. (GRUB): Free Stock Analysis Report

Apple Inc. (AAPL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.